Navigation Links
Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
Date:5/15/2012

LAUSANNE and VILLARS-SUR-GLÂNE, Switzerland, May 15, 2012 /PRNewswire/ --

Debiopharm Group™ (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and commercialization in Switzerland of the 1-, 3- and 6-month formulations of Pamorelin® LA and of the 3-month formulation of Salvacyl®. The agreement came into effect on 9 May 2012. Pamorelin® LA, which contains the active substance triptorelin in the form of pamoate salt, is indicated in the treatment of advanced hormone-dependent prostate cancer, endometriosis and female infertility. Salvacyl® is indicated in the treatment of severe sexual deviation in men. The 1- and 3-month formulations of Pamorelin® LA are available immediately, while the introduction of the 6-month formulation of Pamorelin® LA and Salvacyl® will be communicated by Vifor Pharma at a later date.

Developed by Debiopharm, the products Pamorelin® LA and Salvacyl® are manufactured by Debio R.P. in Martigny, Debiopharm's site for applied research, controlled release formulation development and production.

"We are very happy that Vifor Pharma and Debiopharm can offer a drug with the added value of Pamorelin® LA to prostate cancer patients and that Pamorelin® LA will be marketed in Switzerland by a well-established Swiss company such as Vifor Pharma," emphasised Rolland-Yves Mauvernay, founder and President of Debiopharm.

"With Debiopharm we have found a renowned Swiss partner. This move will enable us to provide patients and doctors with an innovative product in the areas of oncology and gynaecology," added Josef Troxler, General Manager of the Swiss affiliate of Vifor Pharma.

About Pamorelin® LA (active ingredient : triptorelin)

Triptorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). In 1982, Debiopharm signed a licensing agreement for triptorelin with Tulane University in the US. Debiopharm developed and registered three slow-release formulations (1, 3 and 6 months) of triptorelin pamoate in Europe and the US. These product formulations are currently available under the names of Trelstar® in the US and Decapeptyl® /Pamorelin® in Europe. In Switzerland, the product received marketing authorization for the treatment of advanced hormone-dependent prostate cancer and endometriosis, as well as for downregulation in association with fertility treatment.

About Debiopharm Group

Debiopharm Group specializes in biopharmaceutical development. The group acquires licences of promising biological products and molecules and develops them further with the objective of achieving global registration. In addition, the group works in the field of diagnostic companions and out-licences to pharmaceutical partners for sales and marketing. The Group finances all its activities independently while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation and regulatory affairs. Established in 1979 and based in Lausanne (Switzerland), Debiopharm Group has developed five products that are commercialized successfully by its partners throughout the world.

Debio R.P., based in Martigny, is a pharmaceutical research, development and production company. The production site of Debio R.P. has been certified by Swissmedic (Switzerland) and ANVISA (Brazil), and inspected and registered by the FDA (USA) and the KFDA (South Korea). Debio R.P. forms part of the Debiopharm Group and employs 130 people, half of whom are university graduates or engineers.

For more information about the Debiopharm Group, please visit: http://www.debiopharm.com.

About Vifor Pharma

Vifor Pharma, a company of the Galenica Group, is a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Vifor Pharma, headquartered in Zurich, Switzerland, has an increasingly global presence and a broad network of affiliates and partners around the world. The Swiss affiliate is located in Villars-sur-Glâne (Canton Fribourg).

For more information about Vifor Pharma and its parent company Galenica, please visit http://www.viforpharma.com and http://www.galenica.com.

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com

Vifor Pharma Media Contact
Beatrix Benz
Head of Global Communications
Vifor Pharma Ltd.
Tel.: +41-58-851-80-00
Fax: +41-58-851-80-03
beatrix.benz@viforpharma.com

Debio R.P. Contact
Cédric Sager
CEO
Tel.: +41(0)27-721-79-00
Fax: +41(0)27-721-79-01
csager@debiopharm.ch    

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44(0)20-7379-5151
bhudspith@maitland.co.uk
   


In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com
   



'/>"/>
SOURCE The Debiopharm Group and Vifor Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
2. Augurix Diagnostics Receives the 2011 Debiopharm /Valais Award for its Point-of-care Diagnostic Test for the Early Detection of Celiac Disease
3. Continuity as Debiopharm Group™ Management Moves Forward
4. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
5. Debiopharm Group™ and Aurigene Nominate Development Candidate
6. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
7. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
8. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
11. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 The key factors ... increasing diabetic population, accelerating economic growth and increasing healthcare expenditure. ... are higher life expectancy of ESRD patients, rising demand for ... However, the expansion of the market is hindered by high ... ...
(Date:3/23/2017)... , March 23, 2017 As a ... along with the prevalence of allergic diseases, cutting ... are currently revolutionising the ways in which pharmaceutical ... Allergies 2017 promises to be both a high ... the allergy interest groups, immunologists, research scholars and ...
(Date:3/23/2017)... AUSTIN, Texas , March 23, 2017 /PRNewswire/ ... www.digitalpharmacist.com ), a rapidly growing digital ... PocketRx, a mobile app that allows patients to ... including multi-store locations such as Denver Health Pharmacy, ... app. The acquisition helps Digital Pharmacist accelerate its ...
Breaking Medicine Technology:
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI “Hall ... modular industry or whose acts have had a significant impact on the careers of all ... and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. The ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... Angeles, CA (PRWEB) , ... March 23, 2017 ... ... A funding investment in Los Angeles based healthcare technology company California Healthcom Group ... portfolio into the US, and healthcare arena. With headquarters in California, CHG is ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri ... the greater Fort Collins area, has unveiled a collaboration with nonprofit Big Bones ... Donations to this worthy cause may now be made at http://bigbonescaninerescue.com/ . ...
Breaking Medicine News(10 mins):